Dr Richard Lipscombe from Proteomics International (ASX:PIQ) shares their new non-invasive diagnostic tool, Promarker. This blood test targets individuals with chronic acid reflux, a precursor to esophageal adenocarcinoma, aiming to offer a less invasive alternative to endoscopy, which is costly and uncomfortable.